Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5729MR)

This product GTTS-WQ5729MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5729MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5647MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ13853MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ6036MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ961MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ3154MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ5683MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ13879MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ13885MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW